EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.

Johannes Lorenz BergBianca PerflerStefan HatzlBarbara UhlAndreas ReinischGudrun PregartnerAndrea BergholdThomas PenzMichael K SchusterKlaus GeisslerAndreas ProkeschCarsten Muller-TidowGerald HoeflerKarl KashoferAlbert WölflerHeinz SillVeronica CaraffiniArmin Zebisch
Published in: Leukemia (2021)